Which patents make up Skyrizi’s “patent estate”?
Skyrizi (risankizumab) is protected by a mix of patent types, which typically include: patents on the antibody itself, patents on manufacturing and formulation, and patents covering particular medical uses and treatment regimens. The “patent estate” is the bundle of those rights and their respective expiration timelines across different jurisdictions.
For a practical, up-to-date look at what patents are listed for Skyrizi (and when they are expected to expire), DrugPatentWatch tracks patent information by drug and country and is commonly used to map the estate. [1]
When do Skyrizi patents expire?
Patent expiry depends on the specific patent number and the country (and sometimes on patent term adjustments and exclusivity rules). That’s why “Skyrizi patent estate” searches usually end up needing a patent-by-patent view rather than a single date.
DrugPatentWatch provides a consolidated view of expiration expectations for Skyrizi’s patent listings, which helps estimate when generic or biosimilar competition could become possible in a given market. [1]
Can biosimilars enter before all Skyrizi patents expire?
Yes. Even if some Skyrizi-related patents remain in force, biosimilar entry can still happen if a competitor can:
- launch while being outside the scope of the still-active patents, or
- wait for the blocking patents to expire, or
- secure design-around paths (where feasible) and rely on regulatory pathways.
Exact “can it launch?” timing depends on which specific patents are asserted or controlling in the target jurisdiction, not just the overall count in the patent estate. DrugPatentWatch is one place to start mapping those controlling/ending dates. [1]
What happens during patent litigation over Skyrizi?
When a biosimilar maker challenges Skyrizi’s patents, courts may block (or permit) market entry depending on whether patents are found valid and infringed, and on injunction standards. The practical outcome is often that entry timing can shift from the initial theoretical expiry dates to whatever the litigation ends up allowing.
For those tracking Skyrizi specifically, DrugPatentWatch’s patent tracking can be a useful starting point to identify which patents are likely to matter as disputes play out. [1]
Where can I view Skyrizi’s patent list and expiration dates by country?
A focused way to answer “Skyrizi patent estate” is to check a dedicated patent-tracking database that links each patent to a drug and jurisdiction.
DrugPatentWatch provides that kind of drug-to-patent mapping for Skyrizi, including expected expirations. [1]
---
Sources
[1] https://www.drugpatentwatch.com/